Enliven Therapeutics (ELVN) Competitors

Enliven Therapeutics (NASDAQ:ELVN) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, community ranking, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Does the media refer more to ELVN or CYTK?

In the previous week, Cytokinetics had 6 more articles in the media than Enliven Therapeutics. MarketBeat recorded 20 mentions for Cytokinetics and 14 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 0.66 beat Cytokinetics' score of 0.35 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has better earnings and valuation, ELVN or CYTK?

Enliven Therapeutics has higher earnings, but lower revenue than Cytokinetics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$71.58M	-$1.92	-10.31
Cytokinetics	$19.22M	205.16	-$526.24M	-$5.29	-6.24

Which has more volatility and risk, ELVN or CYTK?

Enliven Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500.

Is ELVN or CYTK more profitable?

Enliven Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -17,906.25%. Cytokinetics' return on equity of 0.00% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-29.46%	-27.33%
Cytokinetics	-17,906.25%	N/A	-50.21%

Do analysts rate ELVN or CYTK?

Enliven Therapeutics presently has a consensus price target of $37.25, suggesting a potential upside of 88.16%. Cytokinetics has a consensus price target of $70.92, suggesting a potential upside of 114.83%. Given Cytokinetics' higher possible upside, analysts clearly believe Cytokinetics is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cytokinetics	0 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

Do insiders and institutionals hold more shares of ELVN or CYTK?

95.1% of Enliven Therapeutics shares are owned by institutional investors. 25.9% of Enliven Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Cytokinetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Does the MarketBeat Community prefer ELVN or CYTK?

Cytokinetics received 818 more outperform votes than Enliven Therapeutics when rated by MarketBeat users. However, 92.86% of users gave Enliven Therapeutics an outperform vote while only 79.83% of users gave Cytokinetics an outperform vote.

Company	Underperform	Outperform
Enliven Therapeutics	Outperform Votes 13 92.86%	Underperform Votes 1 7.14%
Cytokinetics	Outperform Votes 831 79.83%	Underperform Votes 210 20.17%

Summary

Enliven Therapeutics beats Cytokinetics on 10 of the 18 factors compared between the two stocks.